Skip to main content

CAP TODAY/AstraZeneca Webinar: Universal Testing for HRD in Ovarian Cancer: A Pathologist’s Perspective

Thank you

This live web event has ended. Thank you for attending.

Description



Universal Testing for
HRD in Ovarian Cancer:
A Pathologist's Perspective

Why should you register now for this webinar?

  • Learn the role of homologous recombination deficiency
    (HRD) in the development of ovarian cancer
  • Explore the rationale for expanded biomarker testing in
    advanced ovarian cancer
  • Discuss strategies to maximize testing efficiency with
    pathologist-initiated testing
Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenter: Samuel Caughron, MD, FCAP
You will have the opportunity to ask questions of our distinguished presenter.

CAP TODAY does not endorse any of the products or services named within.
This webinar is sponsored by AstraZeneca.
©2020 AstraZeneca. All rights reserved. US-39363 Last Updated 4/20

Contributors

  • Bob McGonnagle

    Publisher, CAP TODAY

  • Sam Caughron, MD

    Pathologist, President & CEO, MAWD Pathology Group
    Chair of Pathology & Medical Director of Clinical Laboratory
    Advent Health Kansas City
    Lenexa, Kansas

May 7, 2020
Thu 2:00 PM EDT

Duration 1H 0M

This live web event has ended.

For Technical Support
support@blueskyelearn.com
+1 (858) 201-4136